Indegene (BOM:544172) EBIT per Share : ₹16.89 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Indegene EBIT per Share?

Indegene's EBIT per Share for the three months ended in Sep. 2024 was ₹5.31. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₹16.89.

During the past 12 months, the average EBIT per Share Growth Rate of Indegene was 193.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Indegene's EBIT per Share or its related term are showing as below:

BOM:544172's 3-Year EBIT Growth Rate is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 8.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Indegene's EBIT for the three months ended in Sep. 2024 was ₹1,281 Mil.

Indegene EBIT per Share Historical Data

The historical data trend for Indegene's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indegene EBIT per Share Chart

Indegene Annual Data

Trend

Mar21

Mar22

Mar23

EBIT per Share

11.31

9.66

16.15

Indegene Quarterly Data
	Mar21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial				4.39	4.72	5.96	5.63	5.31

Indegene EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Indegene's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3863.38	/	239.269
=	16.15

Indegene's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1281	/	241.316
=	5.31

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16.89

Indegene (BOM:544172) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Indegene EBIT per Share Related Terms

Thank you for viewing the detailed overview of Indegene's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Indegene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Indegene Ltd (BOM:544172) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

INDGN:India

Address

Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045

Website

https://www.indegene.com

Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.

Indegene Headlines

No Headlines